These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 26019218)

  • 21. Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts.
    Aliperta R; Cartellieri M; Feldmann A; Arndt C; Koristka S; Michalk I; von Bonin M; Ehninger A; Bachmann J; Ehninger G; Bornhäuser M; Bachmann MP
    Blood Cancer J; 2015 Sep; 5(9):e348. PubMed ID: 26383821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
    Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.
    Mardiros A; Forman SJ; Budde LE
    Curr Opin Hematol; 2015 Nov; 22(6):484-8. PubMed ID: 26457961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.
    Baroni ML; Sanchez Martinez D; Gutierrez Aguera F; Roca Ho H; Castella M; Zanetti SR; Velasco Hernandez T; Diaz de la Guardia R; Castaño J; Anguita E; Vives S; Nomdedeu J; Lapillone H; Bras AE; van der Velden VHJ; Junca J; Marin P; Bataller A; Esteve J; Vick B; Jeremias I; Lopez A; Sorigue M; Bueno C; Menendez P
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32527933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models.
    Mu-Mosley H; Ostermann L; Muftuoglu M; Vaidya A; Bonifant CL; Velasquez MP; Gottschalk S; Andreeff M
    Front Immunol; 2022; 13():880108. PubMed ID: 35615350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Preparation of a dual-specific antibody targeting human CD123 and exploration of its anti-acute myeloid leukemia effects].
    Zhou T; Chen ML; Zhang CY; Liu XY; Wang ZZ; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):225-232. PubMed ID: 38716593
    [No Abstract]   [Full Text] [Related]  

  • 27. Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment.
    Nair-Gupta P; Rudnick SI; Luistro L; Smith M; McDaid R; Li Y; Pillarisetti K; Joseph J; Heidrich B; Packman K; Attar R; Gaudet F
    Blood Cancer J; 2020 Jun; 10(6):65. PubMed ID: 32483120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells.
    Bianchi M; Reichen C; Croset A; Fischer S; Eggenschwiler A; Grübler Y; Marpakwar R; Looser T; Spitzli P; Herzog C; Villemagne D; Schiegg D; Abduli L; Iss C; Neculcea A; Franchini M; Lekishvili T; Ragusa S; Zitt C; Kaufmann Y; Auge A; Hänggi M; Ali W; Frasconi TM; Wullschleger S; Schlegel I; Matzner M; Lüthi U; Schlereth B; Dawson KM; Kirkin V; Ochsenbein AF; Grimm S; Reschke N; Riether C; Steiner D; Leupin N; Goubier A
    Cancer Immunol Res; 2024 Jul; 12(7):921-943. PubMed ID: 38683145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production.
    Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ
    Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
    Busfield SJ; Biondo M; Wong M; Ramshaw HS; Lee EM; Ghosh S; Braley H; Panousis C; Roberts AW; He SZ; Thomas D; Fabri L; Vairo G; Lock RB; Lopez AF; Nash AD
    Leukemia; 2014 Nov; 28(11):2213-21. PubMed ID: 24705479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-cell Activity against AML Improved by Dual-Targeted T Cells Stimulated through T-cell and IL7 Receptors.
    Krawczyk E; Zolov SN; Huang K; Bonifant CL
    Cancer Immunol Res; 2019 Apr; 7(4):683-692. PubMed ID: 30782669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
    Zhou L; Liu X; Wang X; Sun Z; Song XT
    Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia.
    Kubicka E; Lum LG; Huang M; Thakur A
    Front Immunol; 2022; 13():899468. PubMed ID: 36389764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex.
    Ersvaer E; Hampson P; Wendelbo Ø; Lord JM; Gjertsen BT; Bruserud Ø
    Hematology; 2007 Jun; 12(3):199-207. PubMed ID: 17558695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of CD200 and CD123 is a major influential factor in the clinical course of pediatric acute myeloid leukemia.
    Kandeel EZ; Madney Y; Eldin DN; Shafik NF
    Exp Mol Pathol; 2021 Feb; 118():104597. PubMed ID: 33358743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of death (CD95/FAS), activation and adhesion (CD54) molecules on blast cells of acute myelogenous leukemias by TNF-alpha and IFN-gamma.
    Munker R; Andreeff M
    Cytokines Mol Ther; 1996 Sep; 2(3):147-59. PubMed ID: 9384699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Asymmetric anti-CLL-1×CD3 bispecific antibody, ABL602 2+1, with attenuated CD3 affinity endows potent antitumor activity but limited cytokine release.
    Lee E; Lee S; Park S; Son YG; Yoo J; Koh Y; Shin DY; Lim Y; Won J
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37848261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control of acute myeloid leukemia and generation of immune memory in vivo using AMV564, a bivalent bispecific CD33 x CD3 T cell engager.
    Eissenberg LG; Ritchey JK; Rettig MP; Patel DA; Vij K; Gao F; Smith V; Han TH; DiPersio JF
    PLoS One; 2024; 19(5):e0300174. PubMed ID: 38696390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
    Gill S; Tasian SK; Ruella M; Shestova O; Li Y; Porter DL; Carroll M; Danet-Desnoyers G; Scholler J; Grupp SA; June CH; Kalos M
    Blood; 2014 Apr; 123(15):2343-54. PubMed ID: 24596416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.